Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products

ARLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek") today announced that they have signed a non-binding letter of intent (the "LOI") with a U.S. DNA testing platform under which the platform would resell Virotek's selected suite of genomic testing products. The mechanics of the commercial and economic terms are being finalized. Assuming negotiations are completed, the companies expect to name the reselling parties in the coming weeks.

The LOI follows the exclusive U.S. distribution and reseller agreement between Kala and Virotek announced on September 3, 2026. Under that agreement, Kala markets and distributes Virotek's genetic testing and screening program in the United States while Virotek operates the laboratory infrastructure, kit supply, specimen processing, and clinical reporting. Although the initial contract with Virotek is for ophthalmology, KALA facilitated the introduction to the potential reseller and will therefore benefit economically if the deal closes, through a profit-split or commission-based structure, since Virotek will shoulder most of the logistics to fulfill orders.